Bolt Biotherapeutics, Inc. (BOLT) is a Biotechnology company in the Healthcare sector, currently trading at $4.66. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is BOLT = $7 (+50.2% upside).
Valuation: BOLT trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25).
Financials: revenue is $8M, +11.7%/yr average growth. Net income is $33M (loss), growing at +25.1%/yr. Net profit margin is -433.7% (negative). Gross margin is 80.6% (+66 pp trend).
Balance sheet: total debt is $23M against $27M equity (Debt-to-Equity (D/E) ratio 0.87, moderate). Current ratio is 3.59 (strong liquidity). Debt-to-assets is 40.5%. Total assets: $57M.
Analyst outlook: 3 / 8 analysts rate BOLT as buy (38%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 75/100 (Pass), Moat 50/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).
